Peptide API Manufacturing AI Visibility Ranking Trends - November 2026

Tracking how AI platforms recommend peptide api manufacturing ai visibility ranking trends. Updated monthly since April 2026.

Mark Huntley, J.D.
By Mark Huntley, J.D.Growth Strategist & AI Discovery Analyst
13 minutes read
Browse 1 archived editions

Answer capsule

The November 2026 Peptide API Manufacturing benchmark compares 7 companies across 303 AI answers that met its inclusion rules. Bachem leads with 173 recommendations (57.10% of answers). At least one tracked company was recommended in 184 answers; some answers recommended several companies.

The rankings distinguish being mentioned from receiving an affirmative recommendation, then examine placement and the wording used about each company. This edition establishes a baseline; earlier editions measured on a different basis are not used to claim a performance trend. These results describe the answers reviewed, not product quality or customer satisfaction. Differences between monthly samples limit comparisons and do not establish why a result changed.

For the strategic interpretation of this benchmark, read CiteWorks Studio's analysis of How AI Search Is Recommending Peptide API Manufacturing

Industry leaderboard

Questions This Section Answers

  • How do Peptide API Manufacturing rank by recorded AI recommendations in November 2026?

Rank

Company

Recommendations

Recommendation rate

Mention rate

Top 3 rate

#1 rate

Net sentiment

1

Bachem

173

57.10%

85.15%

50.17%

37.29%

0.75

2

AmbioPharm

82

27.06%

36.30%

20.79%

2.64%

0.75

3

Biosynth Peptide Division

63

20.79%

23.43%

13.86%

1.98%

0.89

4

PolyPeptide Group

46

15.18%

23.10%

11.22%

0.33%

0.69

5

CPC Scientific

32

10.56%

17.49%

5.94%

0.99%

0.64

6

CordenPharma Peptides

21

6.93%

16.17%

5.28%

0.33%

0.47

7

CSBio

6

1.98%

2.64%

0.00%

0.00%

0.75

The leaderboard orders companies by how many selected AI answers contained an affirmative recommendation. That count is not the same as reach: a company can appear in many answers without being endorsed in all of them. Ties would require equal recommendation counts, so the printed order should be read as a ranking of recorded endorsements rather than a quality judgment.

Mentions, recommendations and placements answer different questions. A mention records that a company appeared; a recommendation records affirmative endorsement; placements describe where an endorsed company sat within an answer. Top-three and first-place results are nested inside recommendations, so they should not be added to recommendation totals or read as separate wins.

Key findings

Tracked-company answer coverage

Questions This Section Answers

  • How often did the November 2026 Peptide API Manufacturing answer sample recommend any tracked company?

Answer-level result

Qualified answers

Share of qualified answers

At least one tracked company mentioned

302

99.67%

At least one tracked company recommended

184

60.73%

No tracked company recommended

119

39.27%

Multiple tracked companies recommended

125

41.25%

184 distinct answers recommended at least one tracked company. Counting each company recommendation separately gives 423, because an answer can recommend several companies. Answers with no tracked recommendation may still have recommended companies outside this comparison.

Almost every qualified answer named at least one tracked company, but a smaller share recommended one. That gap separates visibility from endorsement: appearing in an answer is not the same as being put forward. Answers without a tracked recommendation may still have named companies outside this comparison, so the coverage figures describe this tracked set only.

Because one answer can recommend several companies, company-level recommendation totals exceed the number of answers carrying any recommendation. The answer-level view and the company-level counts therefore measure different things and should not be combined into a single total.

Reach and affirmative recommendation

Bachem ranks 1 by recommendation count. Mentions: 258 (85.15%); recommendations: 173 (57.10%). Top 3 placements: 152 (50.17%); first-place placements: 113 (37.29%).

Wording about the company: 194 positive, 64 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 67.1%. The net framing score was 0.75 (defined in Methodology).

85 mentions had no recorded recommendation. Of recorded recommendations, 87.86% were Top 3 and 65.32% were first-place.

Bachem leads on recommendation count, and its mentions also frequently carried an endorsement. Even so, a portion of its appearances recorded no recommendation, so reach and endorsement should be read as separate measures. The recommendation-to-mention ratio describes the wording of the recorded answers, not customer behavior or sales.

Placement adds another layer: most of Bachem's recorded recommendations also placed it in the top three, and a majority put it first. Those placements are subsets of the recommendation count, not additional endorsements. Framing was predominantly positive with no negative wording recorded, but that describes answer language rather than company quality.

Recommendation order and placement

Company

Mentions

Recommendation-to-mention ratio

Top 3 / #1 counts

Positive / neutral / negative mentions

Bachem

258

67.1%

152 / 113

194 / 64 / 0

AmbioPharm

110

74.5%

63 / 8

83 / 27 / 0

Biosynth Peptide Division

71

88.7%

42 / 6

63 / 8 / 0

PolyPeptide Group

70

65.7%

34 / 1

48 / 22 / 0

CPC Scientific

53

60.4%

18 / 3

34 / 19 / 0

CordenPharma Peptides

49

42.9%

16 / 1

23 / 26 / 0

CSBio

8

75.0%

0 / 0

6 / 2 / 0

The recommendation-to-mention ratio varies across companies, showing that a company can be named often without being endorsed at the same rate. A high ratio on a small number of mentions is less stable than the same ratio on a larger base, so the sparse profiles deserve caution. These ratios describe recorded answer wording, not conversion or customer preference.

Top-three and first-place counts are nested within recommendations. A company with many recommendations but few first-place placements was endorsed without being ranked at the top of the answer. CSBio recorded no top-three or first-place placements, which is a measured result rather than a missing observation.

Classified framing in context

Company

Positive

Neutral

Negative

Bachem

194

64

0

AmbioPharm

83

27

0

Biosynth Peptide Division

63

8

0

PolyPeptide Group

48

22

0

CPC Scientific

34

19

0

CordenPharma Peptides

23

26

0

CSBio

6

2

0

Framing classifies the wording used when a company appears: positive, neutral or negative. It is not a measure of customer sentiment, reputation or company quality, and it does not explain why a recommendation was or was not recorded. Neutral wording is common for several companies, and no negative mentions were recorded for any tracked company in this sample.

A positive framing score does not establish that the wording caused an endorsement. The classification describes the selected answers only, and the causes of differences between companies remain outside what these counts can show.

Company results in detail

Bachem

Questions This Section Answers

  • What do the November 2026 AI answer results show about Bachem mentions, recommendations and placement?

Bachem ranks 1 by recommendation count. Mentions: 258 (85.15%); recommendations: 173 (57.10%). Top 3 placements: 152 (50.17%); first-place placements: 113 (37.29%).

Wording about the company: 194 positive, 64 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 67.1%. The net framing score was 0.75 (defined in Methodology).

85 mentions had no recorded recommendation. Of recorded recommendations, 87.86% were Top 3 and 65.32% were first-place.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

Bachem ranks first by recommendation count and appears in most qualified answers. Its mentions usually carried an endorsement, and most recorded recommendations also placed it in the top three, with a majority first. Framing was largely positive with no negative wording. These are descriptions of the selected answers, not evidence of market dominance or customer preference.

AmbioPharm

Questions This Section Answers

  • What do the November 2026 AI answer results show about AmbioPharm mentions, recommendations and placement?

AmbioPharm ranks 2 by recommendation count. Mentions: 110 (36.30%); recommendations: 82 (27.06%). Top 3 placements: 63 (20.79%); first-place placements: 8 (2.64%).

Wording about the company: 83 positive, 27 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 74.5%. The net framing score was 0.75 (defined in Methodology).

28 mentions had no recorded recommendation. Of recorded recommendations, 76.83% were Top 3 and 9.76% were first-place.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

AmbioPharm ranks second by recommendation count, with a substantial share of its mentions also carrying an endorsement. Its recommendations were often placed in the top three but rarely first, so its profile combines frequent endorsement with modest top-position presence. Framing was mostly positive with some neutral wording and no negatives. The counts describe answer wording, not sales or customer sentiment.

Biosynth Peptide Division

Questions This Section Answers

  • What do the November 2026 AI answer results show about Biosynth Peptide Division mentions, recommendations and placement?

Biosynth Peptide Division ranks 3 by recommendation count. Mentions: 71 (23.43%); recommendations: 63 (20.79%). Top 3 placements: 42 (13.86%); first-place placements: 6 (1.98%).

Wording about the company: 63 positive, 8 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 88.7%. The net framing score was 0.89 (defined in Methodology).

8 mentions had no recorded recommendation. Of recorded recommendations, 66.67% were Top 3 and 9.52% were first-place.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

Biosynth Peptide Division ranks third by recommendation count and shows the highest recommendation-to-mention ratio among the larger profiles, meaning most of its appearances also carried an endorsement. That ratio rests on a moderate mention base, so it should be read with some caution. Top-three placements were common, first-place placements rare, and framing was overwhelmingly positive.

PolyPeptide Group

Questions This Section Answers

  • What do the November 2026 AI answer results show about PolyPeptide Group mentions, recommendations and placement?

PolyPeptide Group ranks 4 by recommendation count. Mentions: 70 (23.10%); recommendations: 46 (15.18%). Top 3 placements: 34 (11.22%); first-place placements: 1 (0.33%).

Wording about the company: 48 positive, 22 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 65.7%. The net framing score was 0.69 (defined in Methodology).

24 mentions had no recorded recommendation. Of recorded recommendations, 73.91% were Top 3 and 2.17% were first-place.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

PolyPeptide Group ranks fourth by recommendation count. Its mentions were endorsed at a moderate rate, and its recommendations were often placed in the top three but almost never first. Framing was mostly positive with a notable neutral share and no negatives. The profile describes how the selected answers worded appearances, not how customers or the market regard the company.

CPC Scientific

Questions This Section Answers

  • What do the November 2026 AI answer results show about CPC Scientific mentions, recommendations and placement?

CPC Scientific ranks 5 by recommendation count. Mentions: 53 (17.49%); recommendations: 32 (10.56%). Top 3 placements: 18 (5.94%); first-place placements: 3 (0.99%).

Wording about the company: 34 positive, 19 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 60.4%. The net framing score was 0.64 (defined in Methodology).

21 mentions had no recorded recommendation. Of recorded recommendations, 56.25% were Top 3 and 9.38% were first-place.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

CPC Scientific ranks fifth by recommendation count. A majority of its mentions carried an endorsement, though fewer than for the higher-ranked profiles, and its recommendations were placed in the top three less than half the time. Framing was mostly positive with a substantial neutral share. These are recorded answer descriptions rather than measures of product quality or demand.

CordenPharma Peptides

Questions This Section Answers

  • What do the November 2026 AI answer results show about CordenPharma Peptides mentions, recommendations and placement?

CordenPharma Peptides ranks 6 by recommendation count. Mentions: 49 (16.17%); recommendations: 21 (6.93%). Top 3 placements: 16 (5.28%); first-place placements: 1 (0.33%).

Wording about the company: 23 positive, 26 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 42.9%. The net framing score was 0.47 (defined in Methodology).

28 mentions had no recorded recommendation. Of recorded recommendations, 76.19% were Top 3 and 4.76% were first-place.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

CordenPharma Peptides ranks sixth by recommendation count and has the lowest recommendation-to-mention ratio among the tracked companies, meaning many of its appearances carried no endorsement. Neutral wording was more common than positive for this company. Its recommendations, when recorded, were often placed in the top three but rarely first. The figures describe answer wording, not customer sentiment.

CSBio

Questions This Section Answers

  • What do the November 2026 AI answer results show about CSBio mentions, recommendations and placement?

CSBio ranks 7 by recommendation count. Mentions: 8 (2.64%); recommendations: 6 (1.98%). Top 3 placements: 0 (0.00%); first-place placements: 0 (0.00%).

Wording about the company: 6 positive, 2 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 75.0%. The net framing score was 0.75 (defined in Methodology).

2 mentions had no recorded recommendation. Of recorded recommendations, 0.00% were Top 3 and 0.00% were first-place.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

CSBio ranks seventh by recommendation count on a small mention base. Most of its appearances also carried an endorsement, though a couple of mentions had no recorded recommendation. With so few mentions, the share of mentions with a recommendation is unstable and should be read cautiously.

None of its recorded recommendations placed it in the top three or first. Those zero placement counts are measured results, not missing observations; only ratios requiring a nonzero base would be undefined. The wording around CSBio was mostly positive with some neutral mentions and no negative framing.

Earlier ranking snapshot context

Questions This Section Answers

  • How do the available Peptide API Manufacturing snapshots from July 2026 to November 2026 differ in recommendation coverage and measurement scope?

Company

Nov 2026

Bachem

173 / 303 (57.10%)

AmbioPharm

82 / 303 (27.06%)

Biosynth Peptide Division

63 / 303 (20.79%)

PolyPeptide Group

46 / 303 (15.18%)

CPC Scientific

32 / 303 (10.56%)

CordenPharma Peptides

21 / 303 (6.93%)

CSBio

6 / 303 (1.98%)

Company

Nov 2026 rank

Bachem

1

AmbioPharm

2

Biosynth Peptide Division

3

PolyPeptide Group

4

CPC Scientific

5

CordenPharma Peptides

6

CSBio

7

Only months with verified results are shown. Monthly sample coverage is listed in Methodology.

Only one reporting month is shown, so no trend across months can be read from this table. The counts and rates describe the November sample of AI answers, and the ranking reflects recommendation counts within that sample. Earlier editions used a narrower question set and are not treated as a comparable baseline.

AI recommendation trend

Observed recommendation rate (%), Nov 2026

  • Bachemno change
    Nov 202657.1%
  • AmbioPharmno change
    Nov 202627.1%
  • Biosynth Peptide Divisionno change
    Nov 202620.8%
  • PolyPeptide Groupno change
    Nov 202615.2%
  • CPC Scientificno change
    Nov 202610.6%
  • CordenPharma Peptidesno change
    Nov 20266.9%
  • CSBiono change
    Nov 20262.0%

What the November Rankings Show

The November results show that reach, endorsement, placement and framing answer different questions. A company can appear often without being recommended at the same rate, and a recommendation can sit anywhere within an answer's ordering. Reading the leaderboard alone would miss those distinctions, while reading framing alone would say nothing about whether a company was endorsed.

The counts describe the selected AI answers, not customers, sales or company quality. Because one answer can name several companies, company totals overlap and should not be summed. The single-month baseline limits any claim about change, and the causes of differences between companies remain outside what these measurements can establish.

Methodology

Questions This Section Answers

  • How were the November 2026 Peptide API Manufacturing AI visibility measures counted, and what do they not establish?

Question-category coverage: 5 of 11 planned question categories contributed usable observations; 6 contributed none. This describes question-category coverage, not demonstrated platform outages. Findings apply to the available answer set. Mentions require the company to be identified in the answer; incidental uses of its name as an ordinary word are not counted. Mentions require the company to be identified in the answer; incidental uses of its name as an ordinary word are not counted.

The month in the title is the reporting period. The exact dates when the original AI answers were collected have not been verified.

Each company is counted at most once in each answer that meets the benchmark rules. A recommendation requires both an affirmative endorsement and positive wording. Mention, recommendation, Top 3 and first-place rates use the full benchmark answer total. Top 3 and first-place results are included within recommendations, not added to them.

The recommendation-to-mention ratio divides recommendations by mentions. It describes AI answer wording, not customer conversion. Net framing is positive minus negative mentions, divided by all mentions, on a scale from -1 to +1. It does not measure customer satisfaction or company quality.

Market: US; 7 tracked companies. AI services represented: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity.

Research screening totals (answer observations can include repeated questions):

Screening measure

Count

Answers eligible for the limited email report

225

Answers marked relevant during screening

303

Answers marked reserved (screening label)

78

Answers marked irrelevant during screening

56

Captured answer observations

359

Distinct questions

221

Answer observations marked as mentioning a brand

359

Email eligibility and reservation labels do not limit this article: all relevant captured answers are included in its rate denominator.

One answer can mention or recommend several companies. Adding company totals would therefore count some answers more than once. The results describe the AI answers reviewed, not independently verified facts about the companies or their products.

Monthly sample coverage:

Reporting month

Answers included

AI services covered

Services

Nov 2026

303

6

ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity

Earlier editions (July 2026, August 2026, September 2026 and October 2026) used a narrower set of questions. This edition includes all captured answers screened as relevant and establishes a broader baseline. Earlier figures remain in the archive; they are not used to claim a change in performance.

Future editions using the same screening scope can be compared against this baseline.

These results describe the selected AI answers, not independently verified facts about the companies or their products. Mentions require the company to be identified in the answer, and a recommendation requires both affirmative endorsement and positive wording. Top-three and first-place results are included within recommendations rather than added to them.

Only part of the planned question categories contributed usable observations, so findings apply to the available answer set. The exact collection dates have not been verified, and the reporting month is the period label. Recommendation-to-mention ratios and framing scores describe answer wording, not customer conversion, satisfaction or company quality.

Archived editions

Browse earlier published research snapshots for this article. The latest edition remains at the current URL.